Drug Search Results
More Filters [+]

Elsamitrucin

Alternative Names: elsamitrucin
Latest Update: 2008-01-15
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TOP1 Inhibitor,TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Spectrum
Company Location: HENDERSON NV 89052
Company CEO: Thomas J. Riga
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Elsamitrucin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Lymphocytic Chronic B-Cell Leukemia|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Mantle-Cell Lymphoma|Chronic Lymphoid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ELSA 2004-001

P2

Completed

Lymphocytic Chronic B-Cell Leukemia|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Mantle-Cell Lymphoma|Chronic Lymphoid Leukemia

None

Recent News Events

Date

Type

Title